BONE MARROW TRANSPLANT MARKET ANALYSIS

Bone Marrow Transplant Market Size and Trends

Global bone marrow transplant market is estimated to be valued at USD 10.72 Bn in 2024 and is expected to reach USD 14.4 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2024 to 2031.

To learn more about this report, request sample copy

Rising demand for bone marrow transplant due to increasing prevalence of blood cancer such as leukemia and lymphoma globally can drive the market growth. Bone marrow transplant is considered as a primary treatment option for various blood-related diseases. Moreover, rising healthcare spending, availability of advanced treatment options, and growing public awareness regarding bone marrow transplant procedures are some key factors that can drive the market growth. However, high costs associated with bone marrow transplant procedures and shortage of bone marrow donors can hamper the market growth.

Increasing prevalence of cancer, lymphoma, and other diseases

Global bone marrow transplant market growth is driven by rising prevalence of various blood cancers. Cases of blood cancers like leukemia, lymphoma and multiple myeloma have been increasing around the world for various reasons such as increased exposure to toxins and radiations, changing lifestyle factors, growing aged population, and others. Bone marrow or stem cell transplant is a potentially curative treatment option for many patients with these cancers. According to the report published by Global Cancer Research Institutions, worldwide incidence rates of leukemias and lymphomas has increased by over 20% in the past couple of decades. If this trend continues, it is estimated that the annual number of new blood cancer cases will grow to over a million by 2030. Rising incidence of diseases like cancer and lymphoma, which necessitate bone marrow transplants, can drive the market growth in the near future for instance, in January 2022, according to the data published by American Cancer Society, Inc., non-hodgkin lymphoma (NHL) stands is one of the most prevalent cancers in the U.S., comprising approximately 4% of all cancer cases. According to estimates from the same source, around 80,470 individuals (44,120 males and 36,350 females) received NHL diagnoses in the U.S. in 2022, encompassing both adults and children.

Improving Outcomes and Lowering Transplant Risks

There have been major technological and procedural advancements that have helped lower transplantation risks and improved clinical outcomes for bone marrow transplant patients. Developments such as reduced-intensity conditioning regimens, better donor matching algorithms, advances in graft engineering, more effective graft-versus-tumor effects and improved options for preventing and treating complications have collectively boosted success rates of these transplant. For example, use of reduced-toxicity non-myeloablative transplant protocols have made the procedure accessible for older and less fit patients who were earlier not considered eligible. The use of haploidentical donor grafts from family members instead of perfectly matched unrelated donors has broadened the donor pool. Advancements in post-transplant care involving targeted infection prophylaxis, supportive care therapies and immune modulation have also enhanced survival. These evolving best practices and newer technologies are enabling clinicians to adopt more liberal transplant indications. As a result, eligible patient populations are expanding beyond traditional limits. Growing confidence in the procedure has led to increased acceptance amongst patients as a curative approach, thus, boosting demand.